Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "Strides-Pharma-Science"

67 News Found

Stelis Biopharma’s two biologics manufacturing facilities receive EU cGMP accreditation
News | June 18, 2022

Stelis Biopharma’s two biologics manufacturing facilities receive EU cGMP accreditation

Both manufacturing facilities are based out of Benguluru, India


Stelis Biopharma's two biologics manufacturing facilities receive EU cGMP accreditation
Drug Approval | June 16, 2022

Stelis Biopharma's two biologics manufacturing facilities receive EU cGMP accreditation

Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation


Strides receives USFDA approval for Ibuprofen OTC oral suspension
Drug Approval | June 12, 2022

Strides receives USFDA approval for Ibuprofen OTC oral suspension

Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.


Strides receives USFDA approval for Colchicine tablets
Drug Approval | March 11, 2022

Strides receives USFDA approval for Colchicine tablets

Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout


Strides receives USFDA approval for Amantadine Hydrochloride capsules
Drug Approval | February 21, 2022

Strides receives USFDA approval for Amantadine Hydrochloride capsules

To be marketed by Strides Pharma Inc. in the US market


Strides Pharma and subsidiary Universal Corporation enters tie-up with Medicines Patent Pool
News | January 20, 2022

Strides Pharma and subsidiary Universal Corporation enters tie-up with Medicines Patent Pool

They will commercialize molnupiravir in the international markets


Strides receives USFDA approval for influenza medicine
Drug Approval | January 17, 2022

Strides receives USFDA approval for influenza medicine

The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval


Strides to market molnupiravir under the brand name Stripiravir
Drug Approval | December 28, 2021

Strides to market molnupiravir under the brand name Stripiravir

Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2


Stelis commissions vaccine facility in Bengaluru
News | December 21, 2021

Stelis commissions vaccine facility in Bengaluru

The company has started manufacturing the Sputnik Light vaccine


Fifty-five manufacturers selected for Pharma PLI sector
News | November 27, 2021

Fifty-five manufacturers selected for Pharma PLI sector

The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme